The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
AUGMENT: A phase 3, randomized trial to compare efficacy and safety of lenalidomide plus rituximab versus placebo plus rituximab in patients with relapsed/refractory indolent non-Hodgkin lymphoma (NHL).
John Leonard
Consultant or Advisory Role - Celgene
John G. Gribben
Consultant or Advisory Role - Celgene
Honoraria - Celgene; Roche
Marek Trneny
Consultant or Advisory Role - Celgene
Honoraria - Celgene
Research Funding - Celgene
Phillip Scheinberg
No relevant relationships to disclose
Nurgul Kilavuz
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
Meera Patturajan
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
Pierre Fustier
Employment or Leadership Position - Celgene
Stock Ownership - Celgene